Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 1,425 shares at $229.93 ($329K) on 2024-06-25, disclosed to the SEC on 2024-06-26.
Open-market sale of $329k ALNY by CSO & EVP, Head of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $221.71 | 45 | $10K | 3.0% |
| 2 | $224.17 | 9 | $2K | 0.6% |
| 3 | $225.55 | 13 | $3K | 0.9% |
| 4 | $226.82 | 26 | $6K | 1.8% |
| 5 | $228.30 | 96 | $22K | 6.7% |
| 6 | $229.06 | 198 |
| $45K |
| 13.8% |
| 7 | $229.93 | 227 | $52K | 15.9% |
| 8 | $229.93 | 227 | $52K | 15.9% |
| 9 | $231.59 | 74 | $17K | 5.2% |
| 10 | $232.54 | 161 | $37K | 11.4% |
| 11 | $233.53 | 86 | $20K | 6.1% |
| 12 | $234.66 | 138 | $32K | 9.8% |
| 13 | $235.19 | 125 | $29K | 8.9% |
| Total | $230.82 avg | 1,425 | $329K | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |